Britannia Life Sciences Inc (L020) Stock Price & Analysis
L020 Stock Chart & Stats
- Day’s Range
- EUR 0.03 - EUR 0.03
- 52-Week Range
- EUR 0.02 - EUR 0.05
- Previous Close
- EUR 0.03
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 7.28M
- Enterprise Value
- -EUR 5,988.575
- Total Cash (Recent Filing)
- EUR 12.41M
- Total Debt (Recent Filing)
- EUR 211.52K
- Price to Earnings (P/E)
- 0.8
- Beta
- -0.75
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
The sharp reduction in leverage materially improves financial flexibility and lowers balance-sheet pressure. With minimal debt relative to equity, the company has greater capacity to withstand operating volatility and fewer obligations competing with investment or working capital needs.
Equity Asset Cushion
A substantial equity base relative to total assets provides an important capitalization cushion while the company works through weak operations. This supports resilience, limits reliance on creditors, and may give management more flexibility to stabilize or rebuild the business.
Prior Cash Generation
The company has previously demonstrated an ability to generate operating and free cash flow, indicating that cash generation is not entirely absent from the business model. That history provides a possible foundation for recovery if operating performance improves and recent deterioration reverses.
Bears Say
Revenue Contraction
The sharp reduction in revenue points to weak current scale and limited commercial momentum. A smaller and declining top line reduces operating leverage, constrains investment capacity, and makes it harder for the company to absorb fixed costs or build durable profitability.
Weak Core Profitability
Deeply negative operating margins show that the underlying business is not currently converting revenue into sustainable operating earnings. The modest gross margin leaves limited room to cover overhead and invest in growth, making a durable earnings recovery dependent on substantial improvement.
Negative Cash Flow
Current cash burn weakens the company’s ability to fund operations and growth internally, despite its improved balance sheet. If negative cash flow persists, management may face increasing pressure to reduce spending, raise capital, or use existing resources to support the business.
Britannia Life Sciences Inc News
L020 FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
What is Britannia Life Sciences Inc’s market cap?
When is Britannia Life Sciences Inc’s upcoming earnings report date?
How were Britannia Life Sciences Inc’s earnings last quarter?
Is Britannia Life Sciences Inc overvalued?
Does Britannia Life Sciences Inc pay dividends?
What is Britannia Life Sciences Inc’s EPS estimate?
How many shares outstanding does Britannia Life Sciences Inc have?
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics, nutraceutical, and consumer packaged goods (CPG) sectors, operating extensively throughout the United Kingdom and various international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter James Shippen
- Employees
- 28
- Website
- britannia.life
- Address
- 120 Adelaide Street West, Toronto, ON, M5H 1T1, CA
Britannia Life Sciences Inc (L020) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 1 | 7 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 10 | 0 | 2 |
